Agoracom Blog Home

Posts Tagged ‘Covid19 testing’

VIDEO – Empower Clinics Q3-21 Revenue Up 372% YOY, Further Clinic Expansion Under Way

Posted by AGORACOM-JC at 4:37 PM on Monday, November 29th, 2021

Nine-month year-over-year revenue growth of 1,349% 

Empower Clinics continues to fire on all cylinders. This is evident by the strong Q3 results that the company released last week. 

Steven McAuley, Chairman and CEO of Empower commented: 

“This quarter marked the start of a new chapter for the Company and the Empower team. We launched The Medi-Collective brand and clinics, expanded Kai Labs’ facilities and completed the acquisition of MediSure. Each of these milestones is an intrinsic aspect of our strategic growth vision. 

Key Q3-2021 Highlights

  • Revenue from continuing operations of $405,707 compared to $85,960 in Q3 2020, representing 372% year-over-year growth.
  • Revenue from continuing operations of $3,226,335 for nine months YTD 2021 compared to $222,690 for nine months YTD 2020, representing 1,349% year over year growth.

What does CEO Steven McAuley think of these results?

“With positive year-over-year growth coming out of this quarter, we will maximize our fully operational divisions’ capabilities and reach across Canada and the U.S. I’m encouraged by our partnerships and acquisitions progress into Q4 2021 and look forward to the coming months.”

Sit back, relax and watch this powerful interview.

VIDEO – With First New Clinic Launches In Ontario Imminent, Empower Clinics Is Sitting On A Launchpad That Will Keep The Company Flying Through 2022 And Beyond

Posted by AGORACOM-JC at 4:04 PM on Monday, August 16th, 2021

In an interview just over a month ago, Empower Clinics CEO Steve McAuley talked about how the Company is in full-blown growth mode that were best summarized as follows:

“Multiple opportunities have been percolating and I’m going to turn up the heat”

To this added seeing 

“substantially higher market cap” for the Company, as well as, growth that will be “deserving of an uplist”.

Today McAuley and the team at Empower backed up those words with this announcement:

“The Company can now confirm the first new clinic launches will take place in September – location and ribbon cutting ceremonies to be announced – with rollouts of further locations continuing on a regular basis from that point forward.”

In today’s interview McAuley takes shareholders through a detailed overview of the foundation that has now been built, ready to launch and strong enough to catapult Empower into a completely new orbit.
Watch this great interview.  Welcome to the launch pad.   

VIDEO – With 2020 Audit Complete, Empower Clinics CEO Steve McAuley Sees Big Growth For Operations, US Expansion, Market Cap & Uplisting

Posted by AGORACOM-JC at 6:17 PM on Monday, July 5th, 2021

With $US 3.2M in 2020 revenue, representing a 58% increase over the previous year, you would think Empower Clinics CEO Steve McAuley would use his first interview after the filing to celebrate. 

He isn’t. 

Rather, with Fiscal 2020 having come to end more than 6 months ago, the 2020 results are a distant rear view mirror shot of a Company that is in full-blown growth mode and can be best summarized as follows: 

“Multiple opportunities have been percolating and I’m going to turn up the heat” 

To this end McAuley sees a “substantially higher market cap” for the Company, as well as, growth that will be “deserving of an uplist”. 

We could try to list all the powerful things he had to say in this interview – but best we let you watch/hear it straight from Steve in this amazing interview. 

VIDEO – Empower Clinics $CBDT.ca $EPWCF In Advanced Discussions With Large US Pharmacies As Proposed Acquisition Includes Products In 4,000 Canadian Pharmacies $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 5:57 PM on Thursday, June 3rd, 2021

As if today’s press release wasn’t good enough Empower Clinics Announces Major Expansion with Proposed Acquisition of Medisure Canada. Diabetes Tests and Devices Carried In 4,000 Pharmacies and Generated $1.9m in 2020 Revenue, shareholders also received this injection of confidence from CEO

Steve McAuley:

“As I’ve stated to our shareholders on multiple occasions throughout 2021, Empower is in the strongest position it has ever been and will continue to grow every aspect of our business unabated and without interruption. In addition to this acquisition, in the last 30 days alone we have announced expansions of our clinics, gone live on our KAI Saliva RT-PCR test with Air Canada and are very advanced on tripling the size of the KAI Medical Laboratory facility. We are hitting on all cylinders and well on our way to becoming a major vertically integrated healthcare company. I fully expect Empower to have continued strong business announcements in June and throughout 2021″

If that was all, it would be a great day … and it was with $CBDT closing up 16.5% on 7.5M shares to $0.53 … but then Steve shared some powerful information about leveraging this acquisition with large US pharmacies.  

Who did he name? 

Watch this great interview with CEO Steve McAuley.

Universal PropTech $UPI $UPIPF CGO Talks Explosive Covid-19 Diagnostics Market, Clinical Trials, & More $AAT.ca $LPS.ca $EGT.ca

Posted by AGORACOM-AB at 5:16 PM on Thursday, May 13th, 2021
This image has an empty alt attribute; its file name is SMS-Smalljpg-1.jpg

Whereas many companies are just now trying to capitalize on the opportunities presented in the current and massive future of PropTech, Universal PropTech Inc. is actually delivering healthy building solutions and services for developers, owners, and operators in Canada. They’ve also turned their attention towards the global COVID-19 diagnostics market size, which is estimated at USD$84.4 billion in 2020.

We sat down with Frank Carnevale, CGO of Universal Proptech, to talk about the launch of ISBRG Corp’s SpotLight-19(C) clinical trial and new R&D funding, the global COVID-19 diagnostics market, their marketing/distribution plans for the future, and more. Check out the interview now.

VIDEO – Empower Clinics $CBDT.ca $EPWCF Shareholder Q&A With CEO Steve McAuley – Part 1 $DMTK $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 5:23 PM on Friday, May 7th, 2021

PART 1 of Empower Clinics Shareholder Q&A with CEO Steve McAuley.

Topics Covered:

  • Annual Financials
  • KAI Labs
  • Clinics / Rexall
  • KAI Saliva
  • Pipelines

Part 2 next week.

VIDEO – Watch Our Latest Shareholder Q&A With @EmpowerClinics $CBDT $EPWCF

Posted by AGORACOM-JC at 9:06 PM on Thursday, April 15th, 2021

Empower $CBDT.ca $EPWCF Announces DTC Eligibility $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:16 AM on Thursday, April 15th, 2021
  • Company Stock Is Now More Accessible to U.S. Investors
  • United States investors may now more easily trade Empower’s OTC stock (OTC PINK:EPWCF) in addition to Empower’s listing on the CSE (CSE:CBDT) and (FRA:8EC).

VANCOUVER B.C. / April 15, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(FRA:8EC)(OTC PINK:EPWCF) (“Empower” or the “Company”) an integrated healthcare company – serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens – is pleased to announce it is now eligible for Depository Trust Company (“DTC”) services in relation to Empower’s listing on the OTC.

United States investors may now more easily trade Empower’s OTC stock (OTC PINK:EPWCF) in addition to Empower’s listing on the CSE (CSE:CBDT) and (FRA:8EC).

“Convenience is a core part of Empower’s overall strategy for our approach to integrated healthcare, so our capital markets strategy should be the same. I’m thrilled that trading Empower’s shares will now be easier for existing and potential shareholders in the U.S.,” said Steven McAuley, Chairman & CEO of Empower. “Empower has a strong and growing presence in the United States market operationally as well as for investors. We’re confident that we will see enhanced trading liquidity as a result of our DTC eligibility.”

DTC is a subsidiary of the Depository Trust and Clearing Corporation (DTCC), one of the world’s largest securities depositories that manages the electronic clearing and settlement of publicly traded companies. Empower is now eligible to be electronically cleared and settled through the DTC and is therefore considered “DTC eligible”. This electronic method of clearing securities streamlines the process of trading, enhances liquidity, and provides direct access to investors and brokers in the U.S. OTC capital markets.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

Empower Clinics $CBDT.ca $EPWCF Kai Medical Lab Receives Order for Up To 5,000 Covid-19 Tests from Two Film & Television Productions in Excess Of $750,000 $DMTK $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 8:36 AM on Wednesday, April 14th, 2021

  • Announced that Kai Medical Laboratory has received an order for COVID-19 RT-PCR tests that is anticipated to be in excess of $CAD 750,000 from two new film and television productions.

VANCOUVER, BC / April 14, 2021 / EMPOWER CLINICS INC. (CSE:CBDT) (Frankfurt:8EC) (OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company – serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce that Kai Medical Laboratory (“KAI”) has received an order for COVID-19 RT-PCR tests that is anticipated to be in excess of $CAD 750,000 from two new film and television productions.

5,000 TEST ORDER FOR FILM & TELEVISION PRODUCTIONS REPRESENTS REPEAT ORDER BASED ON CONSISTENT PERFORMANCE OF KAI MEDICAL LAB

In early October, shortly after the acquisition of KAI, Empower announced an agreement to process approximately 1,000 COVID-19 RT-PCR tests for a major film & TV production over a 30-day period, with the possibility of more business upon successful completion of the initial tests.

On November 16, 2020 KAI received a repeat and record COVID-19 testing order for approximately 9,000 units in excess of $CAD 1,000,000 over a four-month period.

Today’s announcement represents a repeat Purchase Order of approximately 5,000 units to be processed over just a two-month period. The total revenue from this order is anticipated to be in excess of $CAN 750,000.

“Our team at KAI continues to deliver the type of performance to Tier-1 clients that is worthy of significant repeat business that serves as unequivocal validation of our capabilities,” said Steven McAuley, Chairman & CEO of Empower. “To this end, the magnitude of KAI’s growth and success cannot be overstated as it continues to focus on very active business development and product development, setting a path toward significant North American growth in the midst of tripling its size. KAI is well on its way to becoming a national brand supported by our strong working capital position and a team dedicated to performance.”

As of September 1st, KAI has already processed tests for multiple different film and television productions in key US markets including Los Angeles, Atlanta, New York, Dallas, earning the highest confidence of the industry.

KAI MEDICAL LABORATORY NOW EXPANDING TO TRIPLE CURRENT SIZE IN ANTICIPATION OF ANTICIPATED RAPID TEST GROWTH

On February 16th, Empower announced “KAI Laboratory Now Tripling in Size in Anticipation of Test Volumes by End of Q1”

KAI continues to progress on the design and build out of the laboratory expansion to prepare to meet upcoming demand in a number of areas. First, the continued processing of RT-PCR tests for film & television productions, commercial accounts and enterprise level clients. Second, the full e-commerce impact of KaiTests.com and the national direct-to-consumer marketing programs for KAI Saliva, an FDA, EUA authorized and Health Canada approved at-home Saliva COVID-19 RT-PCR Test. KAI Saliva provides travellers, both foreign and domestic with a simple, fully compliant method to obtain an RT-PCR test and test result prior to arriving or coming back into Canada and USA, or arriving in other countries that have similar executive travel orders.

Finally, KAI Labs continues the development of new direct-to-consumer test protocols that will expand the product offers on Kaitests.com throughout 2021 and beyond.

McAuley added “With each passing month Empower gains more strength and velocity in every aspect of our business from KAI Lab in Dallas to our rapidly expanding clinic operations in Canada and our direct-to-consumer products such as KAI Saliva. All of which are amply funded well into the future with our strongest balance sheet ever thanks to the receipt of more than $12,000,000 in warrant conversions as of last month. We are on a path, a trajectory towards building a great health and wellness company across North America, and I look forward to providing our shareholders with further specifics.”

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/759019-empower-clinics-kai-medical-lab-receives-order-for-up-to-5-000-covid-19-tests-from-two-film-television-productions-in-excess-of-750-000/messages/2311867#message

Empower $CBDT.ca $EPWCF Appoints Kai Medical Laboratory President Yoshi Tyler To Board of Directors $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:29 AM on Tuesday, April 13th, 2021
  • Announced it has appointed Ms. Yoshi Tyler to its board of directors.
  • With a professional and entrepreneurial background in healthcare, Ms. Tyler has more than 13 years of experience providing leadership at Pfizer, Inc., a Fortune 500 pharmaceutical company.
  • This experience has provided her with in-depth knowledge and industry insights to found and lead Kai Medical Laboratory towards unprecedented growth.

VANCOUVER, BC / April 13, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company – serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens – is pleased to announce it has appointed Ms. Yoshi Tyler to its board of directors.

With a professional and entrepreneurial background in healthcare, Ms. Tyler has more than 13 years of experience providing leadership at Pfizer, Inc., a Fortune 500 pharmaceutical company. This experience has provided her with in-depth knowledge and industry insights to found and lead Kai Medical Laboratory towards unprecedented growth. Empower fully acquired Kai Medical Laboratory in October 2020.

“We are delighted to welcome Yoshi as a valued addition to our board of directors,” said Steven McAuley, Chairman & CEO of Empower. “Having diverse leadership continues to improve our company and since our acquisition of Kai Medical Laboratory, Yoshi has led her team to surpass initial growth forecasts and demonstrated an incredible work ethic and passion for excellence. I am privileged to now count Yoshi as a fellow board member in recognition of her talent, performance and passion.”

“I’m thrilled to be contributing to the growth of Empower at another level of the company,” said Yoshi Tyler. “After only a few months as part of the Empower team, I’ve witnessed the benefits of our synergies and know firsthand about the incredible potential we have to become a leading integrated health care company in North America.”

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/758939-empower-appoints-kai-medical-laboratory-president-yoshi-tyler-to-board-of-directors/messages/2311716#message